Spatio-temporal variations and input patterns on the legacy and novel brominated flame retardants (BFRs) in coastal rivers of North China.

Decabromodiphenyl ether (BDE209) has been subject to restrictions since 2018 in developed countries but is still manufacturing in China. Decabromodiphenyl ethane (DBDPE) is widely used as a replacement for BDE209. To better understand the behaviors and fates of these legacy and novel brominated flame retardants (BFRs), water samples were collected from the estuaries of 36 rivers that drain into the Bohai Sea (BS) and North Yellow Sea (NYS) in 2017 and 2018. The results showed that BDE209 was still the predominant compound with a median concentration of 2470 pg L-1, whereas DBDPE had a median concentration of 129 pg L-1. Spatially, relatively high concentrations were observed in the rivers near Laizhou Bay (LB), which is the manufacturing hub of BFRs. BDE209 concentrations were significantly higher in dry season than in wet season, which indicates a dominant process of dilution by precipitation during the wet season. DBDPE concentration showed no significant seasonal difference. This implies that wet deposition was the major additional source of DBDPE during the wet season, and the concentration increased further during the autumn as a result of a time-lag effect. The BFR concentrations in urban rivers were lower than those reported by a study undertaken in August 2013. An increase in the BFR concentrations in rural rivers since 2013 suggested increases in the use and non-point source emissions of BFRs in some remote aquatic environments. The estimated annual inputs of BDE209 and DBDPE into the BS were ∼95.9 kg yr-1 and ∼26.8 kg yr-1, respectively, whereas those into the NYS were ∼24.1 kg yr-1 and ∼8.38 kg yr-1. The results revealed an ecological risk of BDE209 in winter especially in the Xiaoqing River, thus suggesting the impact of BDE209 on the aquatic environment and human health.

[Safety and immunogenicity on three lots of influenza split vaccines among adults].

OBJECTIVE: To evaluate the immunogenicity, safety and stability of the manufacture process regarding three consecutive lots of influenza split vaccines (Anflu). METHODS: A double-blind, randomized and controlled clinical trial was conducted in healthy volunteers. A total of 566 subjects aged 18 to 60 years were recruited and stratified into four age groups before randomly assigned into four groups. Each group would receive one dose of influenza vaccine from either one of the three lots of Anflu or one lot of the licensed control vaccine. Each dose of the vaccines contained 15 microg of each of the H1N1, H3N2 and B type antigen. Safety was assessed through 30-minute observation for immediate allergic reaction and three-day observation after vaccination. HI antibody titers were determined before vaccination and on day 21, after vaccination. RESULTS: Mild adverse reaction was reported and the overall incidence rates on fever of the four groups were from 1.4% to 2.8% but no significant difference was observed between groups. Seroconversion rates of the three viral strains in four groups were 80.3% and above with fold increase as > or = 11.1 and protection rate was > or = 93.4%. For the three lots of investigated vaccines, all of the indexes of the three viral strains in four groups exceeded the standards on EMEA and FDA for influenza vaccine. CONCLUSION: The three consecutive lots of Anflu appeared to be good, with both consistent immunogenicity and safety, indicating the stability of manufacture process.